Logo image of CNSP

CNS PHARMACEUTICALS INC (CNSP) Stock Fundamental Analysis

NASDAQ:CNSP - Nasdaq - US18978H4092 - Common Stock - Currency: USD

1.03  -0.04 (-3.74%)

After market: 1.05 +0.02 (+1.94%)

Fundamental Rating

2

Taking everything into account, CNSP scores 2 out of 10 in our fundamental rating. CNSP was compared to 197 industry peers in the Pharmaceuticals industry. CNSP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CNSP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CNSP has reported negative net income.
In the past year CNSP has reported a negative cash flow from operations.
CNSP had negative earnings in each of the past 5 years.
In the past 5 years CNSP always reported negative operating cash flow.
CNSP Yearly Net Income VS EBIT VS OCF VS FCFCNSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

CNSP has a Return On Assets of -113.57%. This is in the lower half of the industry: CNSP underperforms 77.66% of its industry peers.
With a Return On Equity value of -142.34%, CNSP is not doing good in the industry: 62.94% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -113.57%
ROE -142.34%
ROIC N/A
ROA(3y)-465.36%
ROA(5y)-324.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNSP Yearly ROA, ROE, ROICCNSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CNSP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNSP Yearly Profit, Operating, Gross MarginsCNSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for CNSP has been increased compared to 1 year ago.
CNSP has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CNSP has an improved debt to assets ratio.
CNSP Yearly Shares OutstandingCNSP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M
CNSP Yearly Total Debt VS Total AssetsCNSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -10.58, we must say that CNSP is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.58, CNSP is doing worse than 73.60% of the companies in the same industry.
CNSP has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.02, CNSP is in line with its industry, outperforming 58.38% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -10.58
ROIC/WACCN/A
WACCN/A
CNSP Yearly LT Debt VS Equity VS FCFCNSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

CNSP has a Current Ratio of 4.94. This indicates that CNSP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.94, CNSP is in the better half of the industry, outperforming 73.10% of the companies in the same industry.
CNSP has a Quick Ratio of 4.94. This indicates that CNSP is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CNSP (4.94) is better than 74.11% of its industry peers.
Industry RankSector Rank
Current Ratio 4.94
Quick Ratio 4.94
CNSP Yearly Current Assets VS Current LiabilitesCNSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

CNSP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.00%, which is quite impressive.
EPS 1Y (TTM)96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CNSP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.01% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-7.8%
EPS Next 2Y39.96%
EPS Next 3Y25.01%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNSP Yearly Revenue VS EstimatesCNSP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 50M 100M 150M 200M
CNSP Yearly EPS VS EstimatesCNSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10K -20K -30K -40K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CNSP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CNSP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNSP Price Earnings VS Forward Price EarningsCNSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNSP Per share dataCNSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200 -300

4.3 Compensation for Growth

A more expensive valuation may be justified as CNSP's earnings are expected to grow with 25.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.96%
EPS Next 3Y25.01%

More info and screens

0

5. Dividend

5.1 Amount

CNSP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CNS PHARMACEUTICALS INC

NASDAQ:CNSP (5/30/2025, 8:00:00 PM)

After market: 1.05 +0.02 (+1.94%)

1.03

-0.04 (-3.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13
Earnings (Next)08-12 2025-08-12
Inst Owners4.34%
Inst Owner Change-98.31%
Ins Owners0.03%
Ins Owner Change0%
Market Cap5.62M
Analysts80
Price Target204 (19705.83%)
Short Float %21.5%
Short Ratio2.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)8788.89%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-10702.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.51
P/tB 0.51
EV/EBITDA N/A
EPS(TTM)-358.6
EYN/A
EPS(NY)-1.64
Fwd EYN/A
FCF(TTM)-3.14
FCFYN/A
OCF(TTM)-3.14
OCFYN/A
SpS0
BVpS2.01
TBVpS2.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -113.57%
ROE -142.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-465.36%
ROA(5y)-324.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.94
Quick Ratio 4.94
Altman-Z -10.58
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)74.13%
Cap/Depr(5y)104.48%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.84%
EPS Next Y-7.8%
EPS Next 2Y39.96%
EPS Next 3Y25.01%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-39.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-39.54%
OCF growth 3YN/A
OCF growth 5YN/A